Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VaxGen Inc.-The 1st AIDS Vaccine in Phase 3 HumanTrials -- Ignore unavailable to you. Want to Upgrade?

To: scion who wrote (158)	1/20/2003 9:59:33 PM
From: scion	Read Replies (1) \| Respond to of 250

VaxGen crows to stock market about $8m government backing for AidsVax trial Documents obtained in 1999 by Brian Deer during his Sunday Times investigation, The VaxGen Experiment,of California Aids vaccine company, VaxGen Inc, resulted in federal prosection of Dr William Heyward, who as HIV vaccine chief at the Centers for Disease Control and Prevention cheer-led for VaxGen's technology and arranged $8m in grants for its controversial product whilst secretly engaged to join the company. VaxGen's stock price soared in the quarter following the press release below, which many investors took to imply government endorsement of the company's product. Also on this page is an extract from a May 2001 SEC filing, indicating that although the $8m was not paid directly to the company, it covered clinical trial costs that would otherwise have been incurred by VaxGen -------------------------------------------------------------------------------- Centers for Disease Control Joins VaxGen Study; Awards $8 Million Contract to Supplement HIV Vaccine Research PRNewswire - October 29, 1999 BRISBANE, Calif., Oct. 29 /PRNewswire/ VaxGen Inc. (Nasdaq: VXGN) today announced that the federal Centers for Disease Control and Prevention (CDC) will contribute funds to support additional research at five of the 56 clinics in the United States currently conducting Phase III clinical trials of VaxGen's AIDSVAX vaccine. The CDC will contribute $2 million annually, for four years, to the selected clinics. The focus of the additional research supported by the contract is "to answer critical questions about how this and future vaccine trials may impact the attitudes and behaviors of both trial participants and the communities involved," according to the CDC. "The CDC's support of our trial opens key avenues towards achieving our goals of ending the AIDS epidemic," said Dr. Donald P. Francis, president of VaxGen. "VaxGen will benefit from the vast experience of CDC, the U.S. government's premier HIV prevention organization. In turn, we will be sharing data and data analysis with the CDC." The five clinical sites that will receive the CDC funds are San Francisco Department of Public Health, Fenway Community Health Center in Boston, Ohio State University, Howard Brown Health Center in Chicago, and the University of Washington in Seattle. The contract calls for CDC to assume clinical expenses for trial volunteers at these sites. Each participating site will continue to implement VaxGen's Phase III protocol, as well as conduct the additional research. -------------------------------------------------------------------------------- May 03, 2001 VAXGEN INC (VXGN) Quarterly Report (SEC form 10-Q) Excerpt: "In October 1999, we entered into a collaboration with the federal Centers for Disease Control and Prevention ("CDC") to support research at six of the 56 clinics in the United States currently conducting Phase III clinical trials of our AIDSVAX(R) vaccine. The CDC selected the six sites in the fourth quarter of 1999. Contractual arrangements between the CDC and the clinics were completed in the second quarter of 2000. The participating sites will continue to implement our Phase III protocol, as well as conduct epidemiological, social and behavioral research, which will be shared by the Company and the CDC. The sites will be compensated directly by the CDC for the clinical costs, which would have been incurred by the Company, and for conducting the additional research. The CDC has agreed to contribute approximately $8,000,000 to the participating sites over a four-year period." -------------------------------------------------------------------------------- briandeer.com Go to VaxGen-AidsVax index page briandeer.com

To: scion who wrote (158)	1/21/2003 11:21:31 AM
From: scion	Read Replies (1) \| Respond to of 250

October 17, 2002 DO-02-023 MEMORANDUM TO: Designated Agency Ethics Officials and Inspectors General FROM: Amy L. Comstock Director SUBJECT: 2001 Conflict of Interest Prosecution Survey This Office has completed its annual survey of prosecutions involving the conflict of interest criminal statutes (18 U.S.C. §§ 203, 205, 207, 208, 209) for the period January 1, 2001, through December 21, 2001. Information on five new prosecutions by U.S. Attorneys' offices and the Public Integrity Section of the Department of Justice's Criminal Division was provided to us with the assistance of the Executive Office for United States Attorney's in the Department of Justice. Summaries of the prosecutions reported to this Office can be found on our web site at www.usoge.gov under "Laws and Regulations." ______________________________________________________________________________ 2001 Conflict of Interest Prosecution Survey 2. United States v. William L. Heyward -- Dr. Heyward was the HIV Vaccine Coordinator for the Centers for Disease Control (CDC) until December 1999. While employed by CDC, Dr. Heyward made recommendations about, and participated in the negotiations of, the terms of CDC's collaboration with a private company, VaxGen, Inc. At some point during the negotiations, Dr. Heyward began negotiating for post-retirement employment with VaxGen. The Government maintained that Dr. Heyward's conduct violated 18 U.S.C. § 208 for participating personally and substantially as a Government employee in a particular matter in which, to his knowledge, an organization with whom he was negotiating prospective employment has a financial interest. Pursuant to a settlement agreement dated February 5, 2001, Dr. Heyward paid the Government $32,500, and the Government agreed not to proceed criminally on the alleged violations under 18 U.S.C. § 208. Prosecution handled by the Northern District of Georgia. usoge.gov